# Longeveron (LGVN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LGVN
## Company Profile
- Ticker: LGVN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.6921 USD
- Market cap: 24014443.52 USD
- Last updated: 2026-08-11
## Business Overview
### Regenerative Medicine Company
Longeveron develops allogeneic cellular therapies for rare pediatric and chronic aging-related conditions.
### Laromestrocel
Laromestrocel, formerly Lomecel-B, is manufactured from bone marrow-derived medicinal signaling cells obtained from young healthy adult donors.
### Hypoplastic Left Heart Syndrome
The ELPIS program evaluates laromestrocel as an adjunct to staged surgery in infants with hypoplastic left heart syndrome, an orphan pediatric condition.
### Additional Regenerative Applications
The company is also exploring laromestrocel in aging-related and neurological conditions where inflammation and impaired tissue repair may contribute to disease.
## Why The Stock Is Moving

As of Aug 11, 2026, LGVN closed down 6.00% at $0.6921. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from the Phase 2b ELPIS II study in hypoplastic left heart syndrome are expected in August 2026.

## Recent News
- 2026-08-03 20:05 EST — [Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026](https://biopharmsignal.com/news/LGVN/longeveron-to-report-2026-second-quarter-financial-results-and-host-conference-c-7defe4de) — Source: Longeveron
- 2026-07-23 13:15 EST — [Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors](https://biopharmsignal.com/news/LGVN/deborah-d-ascheim-m-d-elected-to-longeveron-board-of-directors-86a5bee6) — Source: Longeveron
- 2026-07-13 11:05 EST — [Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease](https://biopharmsignal.com/news/LGVN/longeveron-announces-presentation-of-clinical-data-at-the-2026-alzheimer-s-assoc-50c3353b) — Source: Longeveron
- 2026-07-06 20:05 EST — [Longeveron® Appoints Marie Washburn as Chief Financial Officer](https://biopharmsignal.com/news/LGVN/longeveron-appoints-marie-washburn-as-chief-financial-officer-510c9ad9) — Source: Longeveron
- 2026-06-18 13:20 EST — [New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)](https://biopharmsignal.com/news/LGVN/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-a-7acdaf6c) — Source: Longeveron